The global atopic dermatitis treatment market is anticipated to expand at a CAGR of 13.1% during the forecast period, between 2021 and 2028. The market growth is attributed to the increasing prevalence of atopic dermatitis.
Atopic dermatitis is an unceasing inflammatory disease of the skin and has a high incidence in kids with 85% of cases near five years of age. While the situation may occur at any age, it usually starts in childhood, with altering brutality over the years. As children age, the region under the knees and elbows are most generally affected.
In adults, the hands and feet are most usually affected. Scratching the affected area deteriorates the indications, and those affected have an increased risk of skin infections. Most people with atopic dermatitis usually develop a high fever or asthma. Its symptoms include red inflamed rash, flare-ups of itch, and excessive dryness of the skin. The cause of atopic dermatitis engages genetic disorders, immune system malfunctioning, difficulty in the permeability of the skin, and environmental exposure.
Market Trends, Drivers, Restraints, and Opportunities:
- Large patient population pool and launch of new products are major drivers of the market growth.
- Initiation of biologics for the treatment of moderate and severe disease is boosting the uptake of topical calcineurin inhibitors and systematic therapies in the rapid growing markets.
- Severe government guidelines for product approvals can restrain the market growth
- High cost of uptake of generic topical drugs, biologic therapy, and pediatric population can inhibit the market growth.
- The advancements and development in healthcare in developing countries are likely to offer new opportunities during the forecast period.
Scope of Atopic Dermatitis Treatment Market report:
The market report includes an assessment of the market, size, share, trends, segments, and regional markets. Overview and dynamics have been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Atopic Dermatitis Treatment Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2020
|
|
Historic Data
|
2018 & 2019
|
|
Forecast Period
|
2021–2028
|
|
Segmentation
|
Mode of Administration (Topical, Orals, and Injectables), Drug Class (Corticosteroids, Antihistamines, Calcineurin Inhibitors, Immunosuppressant, PDE-4 Inhibitor, Antibiotics, Biologic Therapy, and Emollients), and Distribution Channel (Retail Pharmacies, Drug Stores, Hospital Pharmacies, Mail Order Pharmacies, Online Pharmacies, and Dermatology Clinics)
|
|
Regional Scope
|
Asia Pacific, North America, Europe, Latin America, and Middle East & Africa
|
|
Report Coverage
|
Market scope, analysis, share, competitive analysis, growth facts, restraints, opportunities, and revenue forecast
|
|
Key Players Covered
|
Sanofi SA, Allergan Plc., Novartis International AG, Bristol-Myers Squibb, Bayer AG, Meda Pharmaceuticals, Anacor Pharmaceutical Inc., Pfizer, Astellas Pharma Inc., and Regeneron Pharmaceuticals
|
Atopic Dermatitis Treatment Market Segment Insights :
In terms of mode of administration, the topic dermatitis treatment market can be divided into topical, oral, and injectable. The topical segment is expected to hold a substantial market share, owing to the growing support from public organizations for managing all the operations in clinics and hospitals to provide effective treatment procedures.
Based on drug class, the market can be segmented into corticosteroids, antihistamines, calcineurin inhibitors, immunosuppressant, PDE-4 inhibitor, antibiotics, biologic therapy, and emollients. The corticosteroids segment is projected to register a considerable CAGR during the forecast period, as they are often recommended as first-line therapy for the moderate-severe disease. Also, corticosteroids are utilized as pain relief medication for swelling in the body.
On the basis of distribution channel, the atopic dermatitis treatment market can be divided into retail pharmacies, drug stores, hospital pharmacies, mail order pharmacies, online pharmacies, and dermatology clinics. The hospital pharmacies segment is expected to register a robust growth rate during the forecast period, owing to a huge part of the patient population preferring hospitals for the treatment of the disease and usually buying medicines from hospital pharmacies owing to the availability of drugs.
Based on region, the atopic dermatitis treatment market can be fragmented into Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America is expected to dominate the market during the projection period, owing to high treatment awareness among the patient population across the US and Canada, early adoption of novel medications, healthcare infrastructure, better settlement policies, and rising business partnerships of pharmaceutical companies with contract research organizations.
Segments
By Mode of Administration
- Topical
- Orals
- Injectables
By Drug Class
- Corticosteroids
- Antihistamines
- Calcineurin Inhibitors
- Immunosuppressant
- PDE-4 Inhibitor
- Antibiotics
- Biologic Therapy
- Emollients
By Distribution Channel
- Retail Pharmacies
- Drug Stores
- Hospital Pharmacies
- Mail Order Pharmacies
- Online Pharmacies
- Dermatology Clinics
By Region
- Asia Pacific
- North America
- Europe
- Latin America
- Middle East & Africa
By Key Players
- Sanofi SA
- Allergan Plc
- Novartis International AG
- Bristol-Myers Squibb
- Bayer AG
- Meda Pharmaceuticals
- Anacor Pharmaceutical Inc.
- Pfizer
- Astellas Pharma Inc.
- Regeneron Pharmaceuticals
Competitive Landscape
Key players in the atopic dermatitis treatment market includeSanofi SA, Allergan Plc., Novartis International AG, Bristol-Myers Squibb, Bayer AG, Meda Pharmaceuticals, Anacor Pharmaceutical Inc., Pfizer, Astellas Pharma Inc., and Regeneron Pharmaceuticals. These players engage in mergers & acquisitions, collaborations, agreements, and partnerships to strengthen their geographical presence.
Request For Customization
Enquiry Before Buying
Speak With Analyst
